H. Bekoz Et Al. , "Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.," Annals of oncology : official journal of the European Society for Medical Oncology , vol.28, no.10, pp.2496-2502, 2017
Bekoz, H. Et Al. 2017. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.. Annals of oncology : official journal of the European Society for Medical Oncology , vol.28, no.10 , 2496-2502.
Bekoz, H., Karadurmus, N., Paydas, S., Turker, A., Toptas, T., Tuglular, T. F., ... Sonmez, M.(2017). Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.. Annals of oncology : official journal of the European Society for Medical Oncology , vol.28, no.10, 2496-2502.
Bekoz, H. Et Al. "Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.," Annals of oncology : official journal of the European Society for Medical Oncology , vol.28, no.10, 2496-2502, 2017
Bekoz, H. Et Al. "Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.." Annals of oncology : official journal of the European Society for Medical Oncology , vol.28, no.10, pp.2496-2502, 2017
Bekoz, H. Et Al. (2017) . "Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.." Annals of oncology : official journal of the European Society for Medical Oncology , vol.28, no.10, pp.2496-2502.
@article{article, author={H. Bekoz Et Al. }, title={Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.}, journal={Annals of oncology : official journal of the European Society for Medical Oncology}, year=2017, pages={2496-2502} }